BofA Securities Maintains Inari Medical(NARI.US) With Buy Rating, Announces Target Price $68
Express News | Okami Medical Announces Closing of $32.5M Financing
Okami Medical Announces Closing Of $32.5M Financing
NBCA Announces Endorsement of Inari Medical DEFIANCE Trial
Express News | Inari Medical Announces Partnership With Avf and Nbca on Defiance Trial
Inari Medical Announces Partnership With AVF and NBCA on DEFIANCE Trial
Truist Lowers Price Target on Inari Medical to $46 From $55, Keeps Hold Rating
Inari Medical Inc (NARI) Q2 2024 Earnings Call Highlights: Record Revenue Growth Amidst Challenges
Breaking Down Inari Medical: 9 Analysts Share Their Views
Analysts Offer Insights on Healthcare Companies: Day One Biopharmaceuticals (DAWN) and Inari Medical (NARI)
Inari Medical to Host Analyst and Investor Meeting Following PEERLESS RCT Presentation
Inari Medical to Announce Third Quarter 2024 Financial Results
Bank of America Securities Remains a Buy on Inari Medical (NARI)
Inari Medical, Inc.'s (NASDAQ:NARI) Share Price Matching Investor Opinion
Inari Medical Director Hoffman Sells Over $1.8m in Company Stock
Stifel Initiates Coverage On Inari Medical With Hold Rating, Announces Price Target of $50
Stifel Initiates Inari Medical(NARI.US) With Hold Rating, Announces Target Price $50
Stifel analyst Mathew Blackman initiates coverage on $Inari Medical(NARI.US)$ with a hold rating, and sets the target price at $50.According to TipRanks data, the analyst has a success rate of 49.0%
Reasons to Retain Inari Medical Stock in Your Portfolio for Now
Piper Sandler Maintains Inari Medical(NARI.US) With Hold Rating, Maintains Target Price $50
Piper Sandler analyst Adam Maeder maintains $Inari Medical(NARI.US)$ with a hold rating, and maintains the target price at $50.According to TipRanks data, the analyst has a success rate of 59.9% and
North America Clot Management Devices Market Outlook to 2033 Featuring Boston Scientific, Inari Medical, Medtronic, Penumbra, and Teleflex